English | Español
Press release submission | May 25, 2022

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

Press release submission | May 22, 2022

New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients who had Histologic Inflammation on Baseline Biopsy

Press release submission | May 21, 2022

Good Days Partners With Annexus Health to Streamline the Patient Assistance Enrollment Process for Patients With Retinal Disease

Press release submission | May 20, 2022

Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

Press release submission | May 13, 2022

Glycostem announces new data presentation at EHA 2022 Congress highlighting early safety and clinical course of oNKord® in patients with Acute Myeloid Leukemia

Press release submission | May 13, 2022

Idorsia U.S. Announces First Wave of Patients Prescribed QUVIVIQ (daridorexant) through Partnership with Pharmacy Services Provider

Press release submission | Apr 28, 2022

Leading Physician and Telehealth Pioneer Advises that Patients With Pulmonary Disorders Can Benefit From Remote Patient Monitoring Devices

Press release submission | Apr 21, 2022

Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)

Trending
+ Technology/Innovation
Patient Daily | May 8, 2025

Medfluence attends 2025 Annual Clinical Assembly as only strategic marketing firm
+ Technology/Innovation
Patient Daily | May 7, 2025

OTO Forum 2025 highlights innovation in ENT
+ Pharmaceuticals
Patient Daily | May 8, 2025

Pacific Research Institute CEO: Hospitals are leveraging 340B's 'perverse incentives to enrich themselves'
+ Pharmaceuticals
Patient Daily | May 8, 2025

National Library of Medicine says compounded drugs like GLP-1 offer tailored alternatives to FDA-approved treatments